Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer

Cieślikowski, Wojciech A; Budna‐Tukan, Joanna; Świerczewska, Monika; Ida, Agnieszka; Hrab, Michał; Jankowiak, Agnieszka; Mazel, Martine; Nowicki, Michał; Milecki, Piotr; Pantel, Klaus; Alix‐Panabières, Catherine; Zabel, Maciej; Antczak, Andrzej

doi:10.3390/cancers12010160

Cited by 37 publications

(29 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[13][14][15][16][17] Moreover, using CellCollector, the detection rate in patients in early cancer stages is more than 50%, 20% higher than the detection rate of the similar product CellSearch. 16,18,19 The high detection rate in early-stage tumors maybe facilitates research on the application of CTCs in the diagnosis of early-stage cancer. A study by He et al reported CTCs detection rate of 15.6% (5/32) in patients with ground-glass nodules and mutations in cancer-related genes, including KIT, SMARCBI, and AP53, in all CTCs-positive patients.…”

Section: Discussionmentioning

confidence: 99%

<p>Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer</p>

Duan¹,

Zhang²,

Wang³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Circulating tumor cells (CTCs) have become potential diagnostic biomarker for several types of cancer, including lung cancer. In this study, we aim to determine whether CTCs detected by CellCollector can be used for early-stage diagnosis of lung cancer. Methods: In this study, we recruited 64 volunteers, among whom 44 were suspected lung cancer patients requiring surgical treatment and 20 were healthy volunteers. We simultaneously analyzed PD-L1 expression in CTCs isolated using the GILUPI CellCollector and copy number variation by next-generation sequencing (NGS). Results: We enrolled a total of 44 patients with suspected lung cancer who required surgery and 20 healthy volunteers. The patients were classified into 4 groups based on their pathological results: benign disease, in situ cancer, microinvasive, and invasive. The CTCs detection rate for each group was 10.00% (1/10), 45% (5/11), 50% (7/14), and 67% (6/9), respectively. Among the patients with lung cancer, the CTCs detection rate increased with disease progression. The rate of CTCs positivity was 52.94% (18/34) in patients who were diagnosed with lung cancer by pathology and 10% (1/10) in patients with benign disease. CTCs were not detected in the control group. The area under the receiver operating characteristic (ROC) curve, a measure for distinguishing patients with primary lung cancer, was 0.715 (95% CI 0.549-0.880, P=0.041). The sensitivity and specificity of the in vivo CTCs detection strategy for the diagnosis of early-stage lung cancer were 52.94% and 90%, respectively. CTCs were associated with clinical pathology but not with the size and location of the nodules. Conclusion: CTCs isolation using the CellCollector in vivo detection method might be effective for distinguishing between benign and malignant nodules and may be used for early-stage diagnosis of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer</p>

Duan¹,

Zhang²,

Wang³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…To overcome this problem, several approaches have been described, such as ultrasensitive sequencing of ctDNA and in-vivo enrichment of CTCs, boosting the sensitivity in general, or including tumor-derived extracellular vesicles as they are more abundant than CTCs [ 21 , 22 , 23 , 24 ]. Most importantly, several research articles show that liquid biopsy analytes can complement each other instead of simply being redundant [ 25 , 26 , 27 ]. This opens the possibility of combining liquid biopsy analytes to increase overall sensitivity for tumor-relevant information, leading to a higher proportion of informative patient blood samples.…”

Section: Discussionmentioning

confidence: 99%

A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer

Hofmann

Sallinger

Haudum

et al. 2020

Cancers

View full text Add to dashboard Cite

Novel androgen receptor (AR) signaling inhibitors have improved the treatment of castration-resistant prostate cancer (CRPC). Nonetheless, the effect of these drugs is often time-limited and eventually most patients become resistant due to various AR alterations. Although liquid biopsy approaches are powerful tools for early detection of such therapy resistances, most assays investigate only a single resistance mechanism. In combination with the typically low abundance of circulating biomarkers, liquid biopsy assays are therefore informative only in a subset of patients. In this pilot study, we aimed to increase overall sensitivity for tumor-related information by combining three liquid biopsy approaches into a multi-analyte approach. In a cohort of 19 CRPC patients, we (1) enumerated and characterized circulating tumor cells (CTCs) by mRNA-based in situ padlock probe analysis, (2) used RT-qPCR to detect cancer-associated transcripts (e.g., AR and AR-splice variant 7) in lysed whole blood, and (3) conducted shallow whole-genome plasma sequencing to detect AR amplification. Although 44–53% of patient samples were informative for each assay, a combination of all three approaches led to improved diagnostic sensitivity, providing tumor-related information in 89% of patients. Additionally, distinct resistance mechanisms co-occurred in two patients, further reinforcing the implementation of multi-analyte liquid biopsy approaches.

show abstract

“…It is placed directly in the torrent A patient's blood through an indwelling catheter (size = 20 G), remains in the vein of the arm for 30 min and allows the capture of CTCs in vivo since the system is in contact with a high volume of blood. The catheter is lined with anti-EpCAM antibody and subsequently allows the characterization of CTCs (immunofluorescence, protein analysis, RT-qPCR, FISH, sequencing, analysis of expression and cell culture) [40,41]. While being safe and easy to use, the CellCollector ® did not outperform CellSearch ® in terms of CTCs yield or sensitivity.…”

Section: Methods: Isolation Identification and Culturementioning

confidence: 99%

“…For CellCollector ® , the sensitivity and specificity of the in vivo CTC detection strategy for the diagnosis of early-stage lung cancer were 52.94% and 90%, respectively [41]. In addition, for CellCollector ® , although the sensitivity of CTC detection needs to be further increased, may suggest that high CTC counts might contribute to the identification of high-risk prostate cancer patients with occult metastases at the time of diagnosis [40].…”

Section: Methods: Isolation Identification and Culturementioning

confidence: 99%

Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers

et al. 2020

View full text Add to dashboard Cite

In recent years, there has been an increase in knowledge of cancer, accompanied by a technological development that gives rise to medical oncology. An instrument that allows the implementation of individualized therapeutic strategies is the liquid biopsy. Currently, it is the most innovative methodology in medical oncology. Its high potential as a tool for screening and early detection, the possibility of assessing the patient’s condition after diagnosis and relapse, as well as the effectiveness of real-time treatments in different types of cancer. Liquid biopsy is capable of overcoming the limitations of tissue biopsies. The elements that compose the liquid biopsy are circulating tumor cells, circulating tumor nucleic acids, free of cells or contained in exosomes, microvesicle and platelets. Liquid biopsy studies are performed on various biofluids extracted in a non-invasive way, and they can be performed both from the blood and in urine, saliva or cerebrospinal fluid. The development of genotyping techniques, using the elements that make up liquid biopsy, make it possible to detect mutations, intertumoral and intratumoral heterogeneity, and provide molecular information on cancer for application in medical oncology in an individualized way in different types of tumors. Therefore, liquid biopsy has the potential to change the way medical oncology could predict the course of the disease.

show abstract

Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer

Cited by 37 publications

References 56 publications

<p>Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer</p>

<p>Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer</p>

A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer

Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers

Contact Info

Product

Resources

About